Medicenna Therapeutics Corp. filed a Form D with the Securities and Exchange Commission on 2026-07-06.
Medicenna Therapeutics Corp. filed a Form D notice of an exempt securities offering with the SEC on July 6, 2026. The filing reports $253K sold. Its industry group is Biotechnology. It names Fahar Merchant (Executive Officer, Director), David Hyman (Executive Officer), Nageatte Ibrahim (Executive Officer) (SEC Form D, July 6, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Medicenna Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-07-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Medicenna Therapeutics Corp.
Free to see. No signup.
More on the people and the money behind Medicenna Therapeutics Corp., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Medicenna Therapeutics Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Medicenna Therapeutics Corp. raises, hires or launches. No email unless you switch it on.
Watch Medicenna Therapeutics Corp. →Get the full cited report on Medicenna Therapeutics Corp.
What the filing shows about Medicenna Therapeutics Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Medicenna Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Medicenna Therapeutics Corp.'s address as 2 Bloor Street W, Suite 903, Toronto, A6 M4W 3E2.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Medicenna Therapeutics Corp. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Medicenna Therapeutics Corp. See pricing
Medicenna Therapeutics Corp. is a registered filer with the SEC (CIK 1807983) and has filed since 2024-05-14. 2 filings are on record, the latest on 2026-07-06.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Medicenna Therapeutics Corp.'s Form D of 2026-07-06 names Fahar Merchant, David Hyman, Nageatte Ibrahim and 6 more as its officers, directors or promoters.
Its new offerings report $14.80M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week. The dot is this raise, $253K, on the same scale — one filing against the whole group's total, so it sits low by construction.
In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.
Checked away from the filing. What is below does not come from the record on sec.gov.
The Investor Relations website contains information about Medicenna Therapeutics's business for stockholders, potential investors, and financial analysts.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Fahar Merchant is named as Executive Officer and Director on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
David Hyman is named as Executive Officer on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
Nageatte Ibrahim is named as Executive Officer on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
Rosemina Merchant is named as Executive Officer on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
Albert Beraldo is named as Director on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
John Geltosky is named as Director on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
Karim Lalji is named as Director on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
Richard Sutin is named as Director on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
Angelos Georgakis is named as Director on the Form D that Medicenna Therapeutics Corp. filed with the SEC on 6 July 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-07-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Medicenna Therapeutics Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Medicenna Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Medicenna Therapeutics Corp. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Medicenna Therapeutics Corp.You get an alert in MentionFox the next time this company shows up.
If you're behind Medicenna Therapeutics Corp.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (ir.medicenna.com).
Each opens in a new tab, filled in for Medicenna Therapeutics Corp.. With no account yet, you sign up free and land on the result.
On these lists: Outside the US raises, week of 2026-07-06 · Biotech raises, week of 2026-07-06
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/medicenna-therapeutics-corp-form-d-26000001